Clinical Trials

Clinical Trial Detail

Return to search results.

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy (ITOMIC)

Complete title: Intensive Trial of OMics in Cancer (ITOMIC) 001- Intensive Longitudinal Monitoring in Subjects with Triple Negative Breast Cancer

Research Study Number       8132
    
Principal Investigator       Tony Blau, MD
    
Phase       Pilot

Look up trial at NIH

Research Study Description

This pilot research trial studies collecting, analyzing, and storing samples from patients with triple negative breast cancer (breast cancer cells that do not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 protein) that has spread to other places in the body receiving anti-cancer therapy. Studying samples of tissue, blood, buccal swab, saliva, and urine in the laboratory from patients receiving anti-cancer therapy may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Eligibility Criteria (must meet the following to participate in this study)

Ages Eligible for Study: 18 Years and older (Adult, Senior)

Genders Eligible for Study: Female

Study Population:

Patients with metastatic triple negative breast cancer treated at Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Inclusion Criteria:

- Subjects have metastatic TNBC and are about to receive treatment with a drug they have not received previously

- Disease suitable for biopsy including bone disease as determined by physical exam or imaging (as assessed by a trained specialist in radiology) or have tumor tissue available from a previous biopsy as standard of care (to be determined by the principal investigator [PI] or his designee)

- Subjects must be medically fit and willing to undergo repeated tissue biopsies or surgical procedures to get tumor tissue

- Procedure-specific signed informed consent prior to initiation of any study-related procedures

- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (or a Karnofsky performance status of >= 50%)

- Agree to allow their de-identified clinical and laboratory data to be posted to publicly available databases such as database of Genotypes and Phenotypes (dbGaP)

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)

Exclusion Criteria:

- Bevacizumab treatment within 4 weeks prior to biopsy

- Anticoagulation therapy, unless reversed at the time of biopsy

- The enrolling study oncologist has decided that the subject is not fit enough to undergo repeated tissue biopsies

- Presence of a condition or abnormality that in the opinion of the enrolling investigator would compromise the safety of the subject or the quality of the data

- Significant bleeding disorder

- Known brain metastases that haven't been treated

- Subjects with a life expectancy of less than 6 months

- Prisoners

- Inability to give informed

Other exclusion criteria may apply.



Research Study Number       8132
    
Contact       Seattle Cancer Care Alliance Intake Office
    
Telephone       800-804-8824 / 206-288-1024
    
   

Keywords
Breast Cancer; Solid Tumors; HER2-Negative; Triple Negative Breast Neoplasms

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials